• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    3D Systems Advances Regenerative Medical Solutions for First-of-its-Kind Peripheral Nerve Repair

    6/26/25 8:30:00 AM ET
    $DDD
    Computer Software: Prepackaged Software
    Technology
    Get the next $DDD alert in real time by email
    • Collaboration with French MedTech company, TISSIUM, has resulted in FDA approval for unique 3D-printed polymeric solution for repair of peripheral nerve damage
    • 3D Systems' bioprinting system enabled production of a 3D-printed bioabsorbable medical device leveraging TISSIUM's proprietary biomorphic programable polymers—a major industry milestone that sets new standard for high resolution elastomeric 3D-printed medical implants
    • Builds on 3D Systems' pioneering work to develop additive manufacturing solutions for regenerative medicine applications
    • 3D Systems' solutions accelerating additive manufacturing use in bioprinting—total market anticipated to reach more than $2 billion by end of 2029

    ROCK HILL, South Carolina, June 26, 2025 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced that its 3D bioprinting technologies have enabled FDA approval for the regenerative repair of peripheral nerve damage. For the last several years, 3D Systems has partnered with TISSIUM, a French MedTech company that is a pioneer in the development of biomorphic programmable polymers for tissue reconstruction, to develop a bespoke 3D printing solution for the repair of damaged peripheral nerves. Combining TISSIUM's expertise and proprietary biomorphic programable polymers with 3D Systems' ground-breaking regenerative medicine bioprinting technologies has resulted in the successful development of a fully bioabsorbable 3D-printed medical device for nerve repair utilizing a unique photopolymer. This device, called COAPTIUM® CONNECT with TISSIUM Light, is a first-of-its-kind, atraumatic, sutureless solution for the repair of peripheral nerves. Earlier this week, TISSIUM announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for this solution. This milestone validates the polymer's clinical potential and paves the way for its use across a broad spectrum of transformative applications. Its unique polymer characteristics enable the production of high-resolution, elastomeric biodegradable implants that are unique in the industry.

    "This is a significant advancement in patient care," said Scott Turner, vice president, advanced systems, 3D Systems. "It has been tremendously rewarding to work alongside the talented team at TISSIUM to design a complete 3D bioprinted solution that offers the potential for patients to recover from peripheral nerve damage. I truly believe this will redefine treatment paradigms and offer hope to individuals that have suffered from the effects of nerve damage in regaining their quality of life."

    This milestone is yet another proof point of 3D Systems' nearly decade-long leadership position in bioprinting. In 2017, 3D Systems entered into a joint development program with United Therapeutics Corporation, the goal of which is to establish an unlimited supply of human lungs, requiring no immunosuppression, allowing all patients with end-stage lung disease to receive transplants which will enable them to enjoy long and active lives. 3D Systems has focused primarily on establishing the 3D printing technology to produce scaffolds meeting the extreme precision and resolution requirements for a functional human lung and to do so in a manner that yields the physical, mechanical, and biocompatibility performance to influence cell behavior and reproduction required for extended use in the human body. Its Print to Perfusion™ process enables 3D printing of high-resolution scaffolds, which can be perfused with living cells to create tissues. Through the combination of bioprinting technology, biocompatible 3D printing materials, and a broad range of cell types including patient-derived cells, the Company's biomedical engineers can construct patient-specific living tissues.

    "Over the past several years, we have made phenomenal progress building upon Chuck Hull's invention of 3D printing, and pushing its capabilities into new frontiers," said Dr. Jeffrey Graves, president & CEO, 3D Systems. "Whether in our medical device business through the production of patient-specific implants and surgical solutions, or through the work our regenerative medicine team is doing, 3D Systems is making a profound impact not only on how healthcare is delivered, but on the quality of patients' lives, and continues to solidify what I believe is an unparalleled role we play in advancing medicine with additive manufacturing applications. This latest accomplishment by TISSIUM, enabled by our unique 3D printing technology, is one more example of how 3D Systems is transforming patient care for a better future."

    According to Markets and Markets1, the global 3D bioprinting market was valued at $1.3 billion in 2024, and is expected to reach $2.4 billion in 2029. Nearly 40 years ago, 3D Systems created the innovation of 3D printing and reimagined the approaches and processes for product development, parts manufacturing, and personalized healthcare through additive manufacturing solutions. The Company's additive manufacturing solutions are transforming how healthcare is delivered. As a pioneer in personalized healthcare solutions, 3D Systems has worked with surgeons for over a decade to plan more than 150,000 patient-specific cases and additively manufacture more than two million implants and instruments for 100+ CE-marked and FDA-cleared devices from its world-class, FDA-registered, ISO 13485-certified facilities in Littleton, Colorado, and Leuven, Belgium. 3D Systems is leveraging this experience to innovate bioprinting technologies to transform patient care. By enabling the fabrication of living tissues, the Company believes its bioprinting technology will unlock the promise and potential — to develop new therapeutics, and to improve patient lives.

    Forward-Looking Statements

    Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions, and current expectations and may include comments as to the company's beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in the company's periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.

    About 3D Systems

    For nearly 40 years, Chuck Hull's curiosity and desire to improve the way products were designed and manufactured gave birth to 3D printing, 3D Systems, and the additive manufacturing industry. Since then, that same spark continues to ignite the 3D Systems team as we work side-by-side with our customers to change the way industries innovate. As a full-service solutions partner, we deliver industry-leading 3D printing technologies, materials and software to high-value markets such as medical and dental; aerospace, space and defense; transportation and motorsports; AI infrastructure; and durable goods. Each application-specific solution is powered by the expertise and passion of our employees who endeavor to achieve our shared goal of Transforming Manufacturing for a Better Future. More information on the company is available at www.3dsystems.com.

    Investor Contact: [email protected]

    Media Contact: [email protected]


    1 Markets and Markets, 3D Bioprinting Market: Growth, Size, Share, and Trends (May 2024).



    Primary Logo

    Get the next $DDD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DDD

    DatePrice TargetRatingAnalyst
    2/13/2024$8.50Overweight
    Cantor Fitzgerald
    8/17/2022$8.00Underperform
    Credit Suisse
    3/1/2022$22.00 → $23.00Underperform
    BofA Securities
    3/1/2022$22.00 → $18.00Underweight
    JP Morgan
    3/1/2022$33.00 → $18.00Hold
    Craig Hallum
    3/1/2022$36.00 → $29.00Buy
    Lake Street
    3/1/2022$24.00 → $22.00Neutral
    B. Riley Securities
    11/8/2021$36.00Buy
    Lake Street
    More analyst ratings

    $DDD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 3D Systems Advances Regenerative Medical Solutions for First-of-its-Kind Peripheral Nerve Repair

      Collaboration with French MedTech company, TISSIUM, has resulted in FDA approval for unique 3D-printed polymeric solution for repair of peripheral nerve damage3D Systems' bioprinting system enabled production of a 3D-printed bioabsorbable medical device leveraging TISSIUM's proprietary biomorphic programable polymers—a major industry milestone that sets new standard for high resolution elastomeric 3D-printed medical implantsBuilds on 3D Systems' pioneering work to develop additive manufacturing solutions for regenerative medicine applications3D Systems' solutions accelerating additive manufacturing use in bioprinting—total market anticipated to reach more than $2 billion by end of 2029

      6/26/25 8:30:00 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • 3D Systems Announces Significant Strengthening of Balance Sheet

      Transactions permanently retire approximately $88 million of debt, 41% of prior balance, at a meaningful discount to parRefinancing extends maturity with issuance of $92 million Convertible Senior Secured Notes due 2030Repurchase of 8 million shares, representing approximately 6% of the Company's outstanding common stock, in connection with the transaction reduces dilution for equity holdersStrong remaining cash reserves support completion of restructuring efforts while maintaining continuity in key growth initiatives ROCK HILL, S.C., June 24, 2025 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced the closing of a series of strategic transactions to retire/refinance its outstandi

      6/24/25 4:24:14 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • 3D Systems Announces Issuance of $92 Million of Convertible Senior Secured Notes due 2030 and Retirement of $180 Million of Existing Convertible Senior Notes due 2026

      ROCK HILL, S.C., June 18, 2025 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced that it has entered into separate, privately negotiated subscription agreements with a limited number of qualified institutional buyers, pursuant to which 3D Systems will issue $92 million aggregate principal amount of its 5.875% convertible senior secured notes due 2030 (the "notes"). The issuance and sale of the notes are expected to close on June 23, 2025, subject to customary closing conditions. The notes will be senior secured obligations of 3D Systems, will be guaranteed by certain subsidiaries of 3D Systems and will bear interest at a rate of 5.875% per annum, payable semiannually in arrears o

      6/18/25 7:00:00 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology

    $DDD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on 3D Systems with a new price target

      Cantor Fitzgerald initiated coverage of 3D Systems with a rating of Overweight and set a new price target of $8.50

      2/13/24 6:31:50 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • Credit Suisse initiated coverage on 3D Systems with a new price target

      Credit Suisse initiated coverage of 3D Systems with a rating of Underperform and set a new price target of $8.00

      8/17/22 7:48:51 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • BofA Securities reiterated coverage on 3D Systems with a new price target

      BofA Securities reiterated coverage of 3D Systems with a rating of Underperform and set a new price target of $23.00 from $22.00 previously

      3/1/22 10:31:36 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology

    $DDD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Erickson Thomas W was granted 29,069 shares, increasing direct ownership by 9% to 349,447 units (SEC Form 4)

      4 - 3D SYSTEMS CORP (0000910638) (Issuer)

      6/13/25 4:55:12 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • Director Kever Jim D was granted 29,069 shares, increasing direct ownership by 6% to 514,919 units (SEC Form 4)

      4 - 3D SYSTEMS CORP (0000910638) (Issuer)

      6/13/25 4:54:33 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • Director Mcclure Charles G was granted 29,069 shares, increasing direct ownership by 19% to 182,117 units (SEC Form 4)

      4 - 3D SYSTEMS CORP (0000910638) (Issuer)

      6/13/25 4:54:03 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology

    $DDD
    SEC Filings

    See more
    • 3D Systems Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - 3D SYSTEMS CORP (0000910638) (Filer)

      6/24/25 4:15:22 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SD filed by 3D Systems Corporation

      SD - 3D SYSTEMS CORP (0000910638) (Filer)

      5/30/25 4:15:20 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • SEC Form 8-K filed by 3D Systems Corporation

      8-K - 3D SYSTEMS CORP (0000910638) (Filer)

      5/20/25 5:01:23 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology

    $DDD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Graves Jeffrey A bought $231,000 worth of shares (60,000 units at $3.85), increasing direct ownership by 6% to 1,091,782 units (SEC Form 4)

      4 - 3D SYSTEMS CORP (0000910638) (Issuer)

      12/18/24 4:54:42 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • Erickson Thomas W bought $265,000 worth of shares (50,000 units at $5.30), increasing direct ownership by 24% to 257,294 units (SEC Form 4)

      4 - 3D SYSTEMS CORP (0000910638) (Issuer)

      11/29/23 4:09:40 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • Erickson Thomas W bought $228,400 worth of shares (50,000 units at $4.57), increasing direct ownership by 32% to 207,294 units (SEC Form 4)

      4 - 3D SYSTEMS CORP (0000910638) (Issuer)

      11/22/23 5:44:05 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology

    $DDD
    Leadership Updates

    Live Leadership Updates

    See more
    • Incora Announces Michael Turner as New Chief Financial Officer

      FORT WORTH, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Incora, a leading global provider of innovative supply chain management solutions in the aerospace, defense and industrial sectors, is excited to announce that Michael Turner is joining Incora as Chief Financial Officer, effective June 2, 2025. Michael will lead the global finance organization, including planning, operational finance, treasury, tax and investor relations. Said Michael, "I'm thrilled to join Incora at such a pivotal and transformative time for the business. The Company's strong value proposition, centered on delivering innovative supply chain solutions, is unmatched in the industry. With a clear focus on operational e

      5/21/25 9:00:00 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • 3D Systems Announces Appointment of Dr. Rebekah Gee as Member of its Medical Advisory Board

      ROCK HILL, S.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Today, 3D Systems (NYSE:DDD) announced the appointment of Dr. Rebekah Gee to the 3D Systems Medical Advisory Board, effective March 1, 2023. Dr. Gee is a recognized expert on public health policy and was elected to the National Academy of Medicine in 2017. Dr. Gee will join six other members of the advisory board who have been named since the board's establishment in May 2022: Dr. Stephen K. Klasko, former President and CEO of Thomas Jefferson University and Jefferson Health;The Honorable David J. Shulkin, former U.S. Secretary of Veterans Affairs;The Honorable Alex Azar, former U.S. Health & Human Services Secretary;Dr. Toby Cosgrove, f

      2/8/23 8:30:00 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology

    $DDD
    Financials

    Live finance-specific insights

    See more
    • 3D Systems Reports First Quarter 2025 Financial Results

      ROCK HILL, S.C., May 12, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the first quarter ended March 31, 2025. Revenue of $95 million as growth in new hardware systems and related services was offset by a decline in materials sales driven primarily by inventory management in the dental aligner market.Previously announced $50 million cost savings initiative proceeding on schedule for completion by mid-2026. Reduction in operating expenses in Q1 continues to reflect the Company's focus on cost and efficiency.Company announcing an additional cost reduction initiative estimated to deliver $20 million incremental savings in 2025 to acceler

      5/12/25 5:00:00 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • 3D Systems Announces Date of First Quarter 2025 Financial Results

      ROCK HILL, S.C., April 30, 2025 (GLOBE NEWSWIRE) -- 3D Systems (NYSE:DDD) announced today it will release its financial results for the first quarter 2025 after the U.S. stock markets close on Monday, May 12, 2025. The company will hold a conference call and simultaneous webcast to discuss these financial results on Tuesday, May 13, 2025 at 8:30 a.m. Eastern Time. First Quarter 2025 Financial Results Conference CallDate: Tuesday, May 13, 2025Time: 8:30 a.m. Eastern TimeListen via webcast: www.3dsystems.com/investorParticipate via telephone: 201-689-8345 The webcast replay will be available approximately two hours after the end of the conference call at www.3dsystems.com/investor.

      4/30/25 4:05:00 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • 3D Systems Reports Fourth Quarter and Full Year 2024 Financial Results

      ROCK HILL, S.C., March 26, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2024. Full-year 2024 revenue of $440 million, above lower end of guidance range, inclusive of a $9 million revenue reduction in Q4 driven by a change in accounting estimates for Regenerative Medicine program milestone recognition. This change in estimate is related to the now anticipated use of pre-clinical human decedent testing, successfully demonstrated by our partner, United Therapeutics, which led to refinement of the milestone technical criteria.Continued reduction in operating expenses in Q4 reflectin

      3/26/25 4:15:00 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology

    $DDD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 3D Systems Corporation

      SC 13G/A - 3D SYSTEMS CORP (0000910638) (Subject)

      11/12/24 12:13:36 PM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G filed by 3D Systems Corporation

      SC 13G - 3D SYSTEMS CORP (0000910638) (Subject)

      11/4/24 10:58:34 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SC 13G/A filed by 3D Systems Corporation

      SC 13G/A - 3D SYSTEMS CORP (0000910638) (Subject)

      10/17/24 10:40:01 AM ET
      $DDD
      Computer Software: Prepackaged Software
      Technology